- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients
Search this article
Description
TTACROLIMUS is a potent immunosuppressant that is now well established for primary immunosuppression in kidney transplantation as well as in other solid organ transplantations, with long-term clinical experience accumulating. In Japan, tacrolimus was approved for the prevention of allograft rejection in patients receiving kidney transplants in April 1996. Since then, it has been used widely in various recipient and donor conditions. This paper summarizes the results of a 3-year experience with tacrolimus at 35 leading institutions for renal transplantation in Japan, focusing on safety data for tacrolimus with special attention to its effects on cardiovascular risk factors.
Journal
-
- Transplantation Proceedings
-
Transplantation Proceedings 34 1600-1603, 2002-08-01
Elsevier BV
